Semax
Also known as: SEMAX, Heptapeptide SEMAX
Buy in shop
Semax from $45/kit
3 verified vendors, ≥99% purity, COAs included.
Key Facts: Semax
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Approved in Russia - Not FDA approved. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
- Administration
- Intranasal spray (most common)
- Typical Dose
- 200-600 mcg intranasal daily
- Frequency
- 1-3x daily, intranasal
- Duration
- 10-30 days typical
Mechanism of Action
Semax increases BDNF and NGF expression, modulates dopamine and serotonin systems, and has anti-inflammatory effects in the brain. It enhances neuroplasticity and protects neurons from oxidative stress and excitotoxicity.
Research Summary
Russian research shows cognitive enhancement, improved memory and attention, and benefits for stroke recovery. Studies demonstrate increased BDNF levels and neuroprotective effects. Used clinically in Russia for stroke, TBI, and cognitive disorders.
Dosing Information
Typical Dosingⓘ
Community experience
200-600 mcg intranasal daily
100-900 mcg daily
1-3x daily, intranasal
Nootropic peptide, used intranasally. Effects are subtle and cognitive. Can be combined with Selank for anxiety/focus.
Research Dosingⓘ
Scientific studies
Doses from clinical practice
Doses from Studies
300-600 mcg intranasal
Up to 3x daily
Duration
10-30 days typical
Administration
Intranasal spray (most common)
Timing & Administration
Best Time to Take
Morning or early afternoon
2-3 times daily, last dose before 3 PM
Food Recommendation
With or without food
Why This Timing?
Semax has stimulating cognitive effects. Morning use maximizes focus benefits during work hours without affecting sleep.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nasal irritation (common)
- ●Headache
- ●Insomnia
- ●Increased anxiety (paradoxical in some)
- ●Nausea
- ●No serious adverse events in trials
- ●Caution with SSRIs and MAOIs
References
- https://pubmed.ncbi.nlm.nih.gov/16996037/
- https://pubmed.ncbi.nlm.nih.gov/14556513/
- https://pubmed.ncbi.nlm.nih.gov/16635254/
Research This Peptide Further
Buy in shop
Semax from $45/kit
3 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does Semax do?
A synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
How does Semax work?
Semax increases BDNF and NGF expression, modulates dopamine and serotonin systems, and has anti-inflammatory effects in the brain. It enhances neuroplasticity and protects neurons from oxidative stress and excitotoxicity.
Is Semax FDA approved?
No, Semax is not currently FDA approved. Current status: Approved in Russia - Not FDA approved. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
What are the side effects of Semax?
Reported side effects include: Nasal irritation (common), Headache, Insomnia, Increased anxiety (paradoxical in some), Nausea. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Semax?
Community-reported common dose: 200-600 mcg intranasal daily (1-3x daily, intranasal). Range: 100-900 mcg daily. Administration: Intranasal spray (most common). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Semax or used in similar applications.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveCerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
CognitiveDihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
CognitiveGB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveNormoftal
Clinical TrialsA synthesized Khavinson peptide bioregulator containing short peptides (2-4 amino acids) derived from retinal tissue. Developed to normalize retinal function and support eye health. Clinical studies in Russia report improved visual function in 95% of patients with various retinal pathologies.
CognitivePE-22-28
PreclinicalA synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
CognitiveWant updates on Semax research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.